Andrew Young

Andrew Young currently serves as the Chief Scientific and Medical Officer at i2o Therapeutics, a position held since November 2023. Prior to this role, Andrew was a Strategic Advisor for New Rhein Healthcare Investors from June 2021 to November 2023. Andrew has significant experience in leadership roles, including serving as Chief Scientific Officer at Intarcia Therapeutics, Inc. from September 2015 to December 2020 and co-founding Phoundry Pharmaceuticals Inc. in March 2015, where optimization of peptide therapeutics was a primary focus. Other roles include VP and Head of Enteroendocrine Biology at GlaxoSmithKline, Founder of Satiogen, CMO at Leptos Biomedical, and VP Sr Research Fellow at Amylin Pharmaceuticals. Andrew has also consulted as a physiologist and fulfilled an academic role as a Lecturer in Physiology at The University of Auckland. Educational credentials include an MB ChB (MD), PhD, MSc, and BSc in Physiology from The University of Auckland.